TrialPath
Recruiting

Multicenter iTBS Neuromodulation for PTSD Treatment

NCT06434766 · Second Affiliated Hospital, Zhejiang University, School of Medicine
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Multicenter Clinical Study on Transcranial Magnetic Stimulation of the Primary Motor Cortex for PTSD Treatment
About this study
The proposed study aims to evaluate the efficacy of intermittent theta-burst transcranial magnetic stimulation (iTBS) targeting primary motor cortex as adjunct treatment for PTSD patients. Compared to traditional repetitive transcranial magnetic stimulation (rTMS), iTBS strategy usually delivers large amounts of pulses in a shorter time period, and its equal efficiency has been demonstrated in several psychiatric disorders such as major depressive disorder (MDD). Through this adequately randomized and sham-controlled study of iTBS for PTSD, this work will provide an alternative and potentially more potent stimulation target for clinical PTSD treatment. This study will also provide a comprehensive assessment of this treatment strategy towards improvements in symptoms, quality of life and brain functioning in PTSD. The ultimate goal of this study is to develop a non-invasive brain stimulation approach targeting a novel site for alleviating symptoms and improving life quality for PTSD patients.
Eligibility criteria
Inclusion Criteria: * Aged between 18 to 65 years old * Right handedness * Have a diagnosis of PTSD meeting DSM-5 criteria * CAPS-5 score\>35 * Under stable medication for at least four weeks * Capable of independently reading and understanding study materials and providing informed consent. Exclusion Criteria: * Current (or past if appropriate) significant neurological or medical disorder, or lifetime history of 1) seizure disorder; 2) primary or secondary CNS tumors; 3) stroke; or 4) cerebral aneurysm. * Primary psychotic disorder, bipolar I disorder, major depressive disorder, or personality disorders * Lifetime history of attempted suicide or HAMD-17 suicide item (item 3) ≥ 3 points * Implanted device (deep brain stimulation) or metal in the brain; a pacemaker, extensive dental work, or any magnetic metal implants and upper body tattoos if choose to do fMRI * Previous experience of rTMS * Pregnancy/lactation, or planning to become pregnant during the study * Current under psychological or other physical treatments
Study design
Enrollment target: 140 participants
Allocation: randomized
Masking: triple
Age groups: adult, older_adult
Timeline
Starts: 2024-10-30
Estimated completion: 2027-06
Last updated: 2026-08-03
Interventions
Device: sham stimulationDevice: intermittent theta-burst stimulation (iTBS)
Primary outcomes
  • • Change in PTSD Symptom Severity (Baseline and 4 weeks after finishing treatment)
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine · other
With: Shanghai Mental Health Center, The Affiliated Kangning Hospital of Ningbo University, The First Affiliated Hospital of Anhui Medical University, Tongji Hospital
Contacts & investigators
ContactHuiqian Huang, Ph.D. · contact · hhq0301@zju.edu.cn · +8618757143725
ContactShanshan Li, Bachelor · contact · 1252037349@qq.com
InvestigatorYuan Shen, M.D., Ph.D. · principal_investigator, Tongji Hospital
InvestigatorChang Yu, M.D. · principal_investigator, The Affiliated Kangning Hospital of Ningbo University
InvestigatorKai Wang, M.D., Ph.D. · principal_investigator, The First Affiliated Hospital of Anhui Medical University
All locations (5)
Shanghai Mental Health CenterRecruiting
Shanghai, Shanghai Municipality, China
First Affiliated Hospital of Anhui Medical UniversityRecruiting
Hangzhou, Zhejiang, China
Second Affiliated Hospital Zhejiang University School of MedicineRecruiting
Hangzhou, Zhejiang, China
The Affiliated Kangning Hospital of Ningbo UniversityRecruiting
Ningbo, Zhejiang, China
Tongji Hospital of Tongji UniversityRecruiting
Shanghai, China
Multicenter iTBS Neuromodulation for PTSD Treatment · TrialPath